Skip to main content

Table 6 Lymphocyte subpopulations: recurrent patients vs. disease-free patients

From: Clinical significance of peripheral blood and tumor tissue lymphocyte subsets in cervical cancer patients

 Blood (n = 43)Tissue (n = 35)
Non-recurrentRecurrentPNon-recurrentRecurrentP
Gran %CD452.22 ± 4.386.65 ± 7.520.14710.66 ± 13.458.28 ± 8.240.682
T %MNC57.32 ± 13.2757.83 ± 11.210.92168.67 ± 19.0171.23 ± 11.520.754
CD4%T57.45 ± 10.6748.50 ± 18.240.07148.07 ± 14.4133.12 ± 13.590.018#
CD8%T30.38 ± 8.5936.41 ± 17.030.15142.87 ± 13.4657.92 ± 10.760.015#
CD4:CD82.14 ± 0.971.65 ± 0.850.1961.32 ± 0.750.62 ± 0.340.032#
rdT %T7.21 ± 4.549.300.6572.73 ± 2.002.22 ± 1.230.571
B % MNC6.13 ± 3.315.61 ± 1.930.6935.36 ± 3.623.65 ± 1.780.270
pDC % MNC0.24 ± 0.120.26 ± 0.160.6960.69 ± 0.840.47 ± 0.410.541
CD11c + % pDC8.05 ± 5.194.63 ± 2.410.2085.92 ± 4.905.27 ± 4.200.769
Baso % MNC0.89 ± 0.631.36 ± 0.910.0910.10 ± 0.170.03 ± 0.080.390
BDCA1+ mDC % MNC0.37 ± 0.190.43 ± 0.100.5950.12 ± 0.150.07 ± 0.050.382
BDCA3+ mDC % MNC0.02 ± 0.0400.022#0.02 ± 0.07.00000.441
Mono % MNC14.97 ± 9.0818.13 ± 10.170.3917.89 ± 7.8310.98 ± 10.670.413
CD14+ Mo % MNC14.35 ± 7.2916.63 ± 4.440.5501.90 ± 2.033.37 ± 3.230.175
CD16+ Mo % MNC2.91 ± 1.894.20 ± 3.910.5605.14 ± 5.307.62 ± 7.460.357
CD16+ %Mono17.40 ± 7.2418.80 ± 12.820.74572.16 ± 13.5871.30 ± 12.180.889
NK %MNC16.85 ± 9.9512.37 ± 4.010.2516.12 ± 13.483.98 ± 6.320.709
CD56hi NK % MNC0.33 ± 0.150.30 ± 0.120.6934.50 ± 12.693.40 ± 5.760.839
CD56lo NK % MNC17.68 ± 10.1714.35 ± 3.590.5271.37 ± 2.100.55 ± 0.600.357
CD56hi %NK2.61 ± 2.192.05 ± 0.580.61664.10 ± 24.3474.82 ± 21.910.337
MDSC % CD33hi1.53 ± 2.844.08 ± 5.800.1552.67 ± 4.161.42 ± 1.300.479
DR- %14 + APC0.58 ± 1.650.08 ± 0.150.55416.21 ± 17.2324.48 ± 22.780.335
DR- %16 + APC1.00 ± 1.680.05 ± 0.060.2721.29 ± 2.182.75 ± 4.980.284
  1. #P values with statistical significance were denoted